Prone Positioning in Infants With Acute Bronchiolitis

Posted June 15, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9:30 A.M. ET, WEDNESDAY, JUNE 17, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the International Congress of European Society of Paediatric and Neonatal Intensive Care.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.11078?guestAccessKey=931bd4b5-dc5d-4ea2-a0e1-7b7f0d12b9a4&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061726

About The Study: Prone positioning in infants with moderate to severe bronchiolitis receiving high-flow nasal cannula support did not significantly reduce escalation of care. However, the wide 95% confidence interval around the observed odds ratio suggests that this study was not definitive and further research is warranted.

Corresponding Author: To contact the corresponding author, Florent Baudin, MD, PhD, email florent.baudin@chu-lyon.fr.

(doi:10.1001/jama.2026.11078)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season

Posted June 15, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 17, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18581?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This surveillance study found that while antigenically drifted viruses predominated and caused substantial morbidity and mortality, influenza vaccines were associated with a reduced risk of influenza among those who were vaccinated, and recommended antivirals remained effective.

Corresponding Author: To contact the corresponding author, Eduardo Azziz-Baumgartner, MD, email Eha9@cdc.gov.

(doi:10.1001/jamanetworkopen.2026.18581)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Gestational Exposure to 10 Classes of Priority Chemicals and Birth Outcomes in the ECHO Cohort

Posted June 15, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 17, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18883?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061726

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This large cohort study of diverse U.S. pregnancies found widespread exposure to 10 classes of environmental chemicals, many of which were associated with differences in gestational age at birth or lower birth weight-for-gestational age z scores. These findings indicate that reducing gestational exposure to chemicals, particularly phthalates or alternative plasticizers and polycyclic aromatic hydrocarbons, could promote healthy deliveries and better child outcomes.

Corresponding Authors: To contact the corresponding authors, email Jessie P. Buckley, PhD, MPH, (Jessie.Buckley@unc.edu) and Tracey J. Woodruff, PhD, MPH, (traceyw@stanford.edu).

(doi:10.1001/jamanetworkopen.2026.18883)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Three-Year Contraceptive Failure Rates During the HER Salt Lake Contraceptive Initiative

Posted June 12, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17273?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061626

Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries

Posted June 12, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18677?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061626

Days at Home After Hip Fracture Among Older Adults With and Without Dementia

Posted June 12, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18658?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061626

Short-Acting Opioid Dose and Patient-Directed Discharge in Hospitalized Patients With Opioid Use Disorder

Posted June 12, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18698?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061626

Sociodemographic, Health Care, and Clinical Factors Associated With Metabolic Bariatric Surgery Uptake Among US Adults With Obesity

Posted June 12, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 16, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18686?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061626

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of individuals with an initial obesity diagnosis, uptake of metabolic bariatric surgery was patterned by demographic, clinical, and health care factors. This finding suggests substantial opportunity to improve access to metabolic bariatric surgery through targeted policies and interventions.

Corresponding Author: To contact the corresponding author, Rafeya V. Raquib, MS, email rraquib@bu.edu.

(doi:10.1001/jamanetworkopen.2026.18686)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events Among US Veterans

Posted June 11, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 15, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.1929?guestAccessKey=d13423b6-0f97-447a-a381-df38354146d7&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: In this cohort study, receipt of the 2024-2025 COVID-19 vaccine was associated with reduced risk of COVID-19–associated major adverse cardiovascular event (MACE), with reductions most prominent in those 75 years or older and those with comorbidities. While the reduction in COVID-19–associated MACE was modest, the substantially larger reduction in all-cause MACE suggests that the vaccine’s protective association extends to the hidden burden of undetected SARS-CoV-2 and its sequelae.

Corresponding Author: To contact the corresponding author, Ziyad Al-Aly, MD, email ziyad.alaly@va.gov.

(doi:10.1001/jamainternmed.2026.1929)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults

Posted June 11, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 15, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.1936?guestAccessKey=e928166b-0148-4f49-a5c9-7e1e089110b2&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: In this test-negative case-control study, 2024-2025 COVID-19 vaccination was associated with reduced likelihood of medically attended COVID-19–associated outcomes among immunocompetent and immunocompromised adults, highlighting the importance of adults receiving recommended COVID-19 vaccinations.

Corresponding Author: To contact the corresponding author, Ryan E. Wiegand, PhD, email rwiegand@cdc.gov.

(doi:10.1001/jamainternmed.2026.1936)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Parent and Child Media Use During Family Meals in US Households

Posted June 11, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2182?guestAccessKey=a766de15-cfec-4035-9fd4-2066f37fd4f2&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: In this study, differences were observed in parent and child mealtime media use patterns among racial and ethnic groups. Specifically, Black parental race was positively associated with paired use; Asian parental race was associated with more individual use. These findings may reflect broader cultural differences in family communication, parental intervention styles, and the role of media in parent-child interaction.

Corresponding Author: To contact the corresponding author, Matthew A. Lapierre, PhD, email mlapierre@arizona.edu.

(doi:10.1001/jamapediatrics.2026.2182)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Acoustic Analysis of Primary Care Patient–Clinician Conversations to Screen for Cognitive Impairment

Posted June 11, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 15, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1868?guestAccessKey=bb6fdcfa-b129-402f-93c4-2e3d5bc49b0c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: In this diagnostic study, machine learning models trained on acoustic features from brief clinical conversations identified cognitive impairment with high accuracy. These findings support the feasibility of passive, speech-based screening during routine primary care.

Corresponding Author: To contact the corresponding author, Joseph T. Colonel, PhD, email joseph.colonel@mssm.edu.

(doi:10.1001/jamaneurol.2026.1868)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Emerging Patterns in Dietary Supplement Use Among US Adults, 1999-2023

Posted June 11, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.19291?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this repeated cross-sectional analysis of NHANES 1999 to 2023, supplement use among U.S. adults increased over time, with diversification beyond multivitamin-multiminerals toward products marketed for immune, anti-inflammatory, gut, skin, or joint health. A substantial increase was observed in older adults. Ongoing monitoring of supplement use trends is needed to understand evolving public health implications.

Corresponding Author: To contact the corresponding author, Chun Sing Lam, PhD, email lamc3@mskcc.org.

(doi:10.1001/jamanetworkopen.2026.19291)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

COVID-19 Vaccine Effectiveness Among Older Adults

Posted June 11, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.19040?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: Vaccines administered in autumn and winter 2025 to 2026 showed approximately 55% effectiveness against symptomatic disease among older adults within 2 months of vaccination. The low uptake of vaccines, which showed substantial short-term effectiveness, suggests missed opportunities for preventing symptomatic COVID-19 among unvaccinated vulnerable groups.

Corresponding Author: To contact the corresponding author, Charlotte Laniece Delaunay, PhD, email c.laniece@epiconcept.fr.

(doi:10.1001/jamanetworkopen.2026.19040)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

An AI-Based OCT System to Detect Diabetic Macular Edema

Posted June 10, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7025?guestAccessKey=d9385aaa-55ec-45a2-8d72-0918a28925e3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: Compared with standard practice, incorporation of the AI-based optical coherence tomography (AI-OCT) system as a secondary screening tool was noninferior with respect to false-positive referral rates and was associated with a substantial reduction in potentially unnecessary diabetic macular edema referrals without compromising sensitivity.

Corresponding Authors: To contact the corresponding authors, email Simon K. H. Szeto, MBChB (simonkhszeto@cuhk.edu.hk) and Carol Y. Cheung, PhD (carolcheung@cuhk.edu.hk).

(doi:10.1001/jama.2026.7025)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes

Posted June 10, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 15, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8492?guestAccessKey=39974582-15cb-42b1-9c06-9adef66b64fe&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061526

About The Study: Among adults with prediabetes at baseline, lifestyle intervention, but not metformin, was associated with a lower burden of multimorbidity. Lifestyle programs may persistently lower the development of chronic conditions.

Corresponding Author: To contact the corresponding author, Marcel E. Salive, MD, email dppmail@bsc.gwu.edu.

(doi:10.1001/jama.2026.8492)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Health Equity After a Colorectal Cancer Screening Program

Posted June 10, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, JUNE 12, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1520?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=061226

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: In this cross-sectional study, following the implementation of an organized population screening program, colorectal cancer screening participation increased and socioeconomic disparities narrowed over time. Overall uptake in Hong Kong remains low, and some disparities persist in younger age groups (age 50-59 years), single households, individuals with a primary and secondary school education, lower-income groups, and public housing residents. Efforts to increase participation are needed in certain groups to ensure health equity.

Corresponding Author: To contact the corresponding author, Jianchao Quan, MD, email jquan@hku.hk.

(doi:10.1001/jamahealthforum.2026.1520)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Internet Searches for Leucovorin, Folate, and Acetaminophen After a White House Autism Announcement

Posted June 9, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JUNE 11, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17910?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: During a press conference on September 22, 2025, President Trump and top health officials endorsed use of leucovorin, a generic drug formulated from folinic acid, for treatment of autism, and urged against acetaminophen use during pregnancy, stating concerns about its risk for development of autism in children. The White House announcement was associated with large increases in internet searches over the subsequent 2 weeks, including more than 1 million additional searches for leucovorin; nearly 81,000 additional purchasing interest searches for leucovorin, folinic acid, or folate; and more than 4 million additional searches for acetaminophen with pregnancy or autism.

Corresponding Author: To contact the corresponding author, Joseph S. Ross, MD, MHS, email joseph.ross@yale.edu.

(doi:10.1001/jamanetworkopen.2026.17910)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Remote Monitoring Approaches to Reduce Readmissions After Infection and Sepsis

Posted June 9, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 10:30 A.M. ET, THURSDAY, JUNE 11, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16641?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: Among trial patients discharged after hospitalization for serious infections, remote monitoring did not increase time spent alive at home but reduced it in those 65 years and older. These findings support reevaluating and tailoring remote monitoring after acute care for sepsis and lower respiratory tract infection to support further alignment with patients’ needs and desire for personalized monitoring.

Corresponding Author: To contact the corresponding author, Sachin Yende, MD, MS, email yendes@upmc.edu.

(doi:10.1001/jamanetworkopen.2026.16641)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Gastric Residual Volume Assessment in Critically Ill Children

Posted June 9, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:00 A.M. ET, FRIDAY, JUNE 12, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10639?guestAccessKey=46672cda-60df-49fb-8607-a7121c939aef&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061226

About The Study: Among critically ill children being enterally fed, not assessing gastric residual volume routinely was noninferior to regular assessments every 6 hours and significantly increased nutritional achievement at 72 hours.

Corresponding Author: To contact the corresponding author, Lyvonne N. Tume, PhD, email Lyvonne.tume@edgehill.ac.uk and l.n.tume@ljmu.ac.uk.

(doi:10.1001/jama.2026.10639)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Sodium Bicarbonate for In-Hospital Cardiac Arrest

Posted June 9, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:00 A.M. ET, THURSDAY, JUNE 11, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10628?guestAccessKey=132e1adf-5bd2-4795-a28e-3f64dc34c7b6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061126

About The Study: There was no significant difference in sustained return of spontaneous circulation between sodium bicarbonate and placebo in adults with in-hospital cardiac arrest. These findings do not support routine administration of sodium bicarbonate for patients with in-hospital cardiac arrest.

Corresponding Author: To contact the corresponding author, Lars Wiuff Andersen, MD, MPH, PhD, DMSc, email lwandersen@clin.au.dk.

(doi:10.1001/jama.2026.10628)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Integrated Telehealth Rehabilitation and Quality of Life in Mechanically Ventilated Adults

Posted June 9, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10:30 A.M. ET, WEDNESDAY, JUNE 10, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10617?guestAccessKey=4fc4ae2c-711e-40d7-8c2d-653464b74aa6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About The Study: In this study, an integrated telehealth-based rehabilitation strategy delivered across intensive care unit, hospital, and postdischarge phases improved 90-day health-related quality of life, potentially influenced by reduced mortality.

Corresponding Author: To contact the corresponding author, Regis Goulart Rosa, MD, PhD, email regis.rosa@hmv.org.br.

(doi:10.1001/jama.2026.10617)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury

Posted June 9, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 8:30 A.M. ET, WEDNESDAY, JUNE 10, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the Critical Care Reviews Meeting 2026.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10616?guestAccessKey=9036397b-730b-4664-bd38-3ee4c5ca8e95&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About The Study: Among patients with severe burn injury, high-dose intravenous vitamin C did not reduce 28-day mortality and persistent organ dysfunction and is possibly harmful.

Corresponding Author: To contact the corresponding author, Christian Stoppe, MD, email christian.stoppe@gmail.com.

(doi:10.1001/jama.2026.10616)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Changes in Genetic Contributions to ASD and ADHD by Year of Diagnosis

Posted June 8, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JUNE 10, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1450?guestAccessKey=38a776c5-f92a-45e4-b74e-4f238a9ffdf7&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About The Study: By analyzing multiple polygenic scores together with simulated expectations, this study could disambiguate among competing hypotheses about scenarios that may be associated with increased rates of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) diagnoses. Findings support broadening diagnostic criteria as an explanation for increasing rates, with implications for understanding changes in risk factors and clinical practice.

Corresponding Authors: To contact the corresponding authors, email Sonja LaBianca, MD, PhD, (sonja.labianca@regionh.dk) and Andrew J. Schork, PhD, (Andrew.Joseph.Schork@regionh.dk).

(10.1001/jamapsychiatry.2026.1450)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia

Posted June 8, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JUNE 10, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1296?guestAccessKey=11f24b55-4e87-4918-ab66-bf4a155ce272&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About The Study: The convergent data in this study support a prospective clinical trial of low-dose lithium orotate to slow disease progression in mild cognitive impairment. Such an approach would prioritize established neuroprotective mechanisms while potentially mitigating the kidney and thyroid risks associated with higher-dose carbonate formulations. If low-dose lithium can indeed meaningfully alter disease trajectory, it would represent a much-needed, accessible, and inexpensive treatment that may be especially relevant in low- and middle-income countries.

Corresponding Author: To contact the corresponding author, Husseini K. Manji, MD, email husseini.manji@psych.ox.ac.uk.

(10.1001/jamapsychiatry.2026.1296)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Wearable Devices and Data Sharing in the US

Posted June 8, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 10, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17733?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this serial survey study, wearable device use increased among U.S. adults, but daily use and clinician-directed data sharing remained limited. These findings suggest that there is a need for approaches to help realize the potential of wearable devices as health care tools, both by broadening uptake and promoting consistent use.

Corresponding Author: To contact the corresponding author, Rohan Khera, MD, MS, email rohan.khera@yale.edu.

(doi:10.1001/jamanetworkopen.2026.17733)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Artificially Sweetened and Sugar-Sweetened Beverage Intake and Risk of Liver Cancer

Posted June 8, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 10, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17754?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this study, increased sugar-sweetened beverage consumption was associated with increased risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. There was little evidence that artificially sweetened beverage intake was associated with liver cancer risk overall or by subtype.

Corresponding Author: To contact the corresponding author, Katherine A. McGlynn, PhD, email mcglynnk@nih.gov.

(doi:10.1001/jamanetworkopen.2026.17754)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Acute Respiratory Tract Infections and Severe Disease Among Hospitalized Children

Posted June 5, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 9, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17575?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060926

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This cohort study found that hospitalized children with acute respiratory tract infections frequently have underlying chronic conditions and often require intensive intervention. Understanding the epidemiologic profile and factors associated with risk of severe disease in this population can inform resource allocation to optimize outcomes for pediatric patients.

Corresponding Author: To contact the corresponding author, Haifa Mtaweh, MD, PhD, email haifa.mtaweh@sickkids.ca.

(doi:10.1001/jamanetworkopen.2026.17575)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Large Language Model Chatbot Conversations vs Public Health Materials and Parental HPV Vaccination Intentions

Posted June 4, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16822?guestAccessKey=fd9934b0-bfd6-48b5-b121-d4ee7c77fda8&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060826

Corresponding Author: To contact the corresponding author, Neil K. R. Sehgal, ME, email Holly Wojcik at hwojcik@seas.upenn.edu.

Egg Allergy Prevalence Before and After Guidelines for Earlier Egg Introduction

Posted June 4, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 8, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2080?guestAccessKey=59ff8f93-17c1-41e9-9ef5-99cc07e28a70&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060826

About The Study: This study provides population-level evidence that updated infant feeding guidelines recommending earlier introduction of egg led to measurable reductions in the population prevalence of egg allergy. The findings suggest that guideline updates informed by randomized trial evidence may be associated with a reduction in food allergy prevalence when implemented effectively.

Corresponding Author: To contact the corresponding author, Jennifer J. Koplin, PhD, email j.koplin@uq.edu.au.

(doi:10.1001/jamapediatrics.2026.2080)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Smartphone Acquisition and Use at Age 13 and Health Outcomes at Age 14

Posted June 4, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 8, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2118?guestAccessKey=f1c86f86-cb45-4887-ae3c-feb03859530c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060826

About The Study: The results of this cohort study suggest that simply smartphone acquisition at age 13 was not associated with depression or with obesity, but was associated with insufficient sleep at age 14; however, the amount of smartphone use was associated with higher odds of all 3 outcomes. Behavioral interventions like limiting smartphone time and keeping smartphones out of bedrooms at night may protect adolescents from potential adverse health outcomes. Findings offer insights to guide caregivers on adolescent smartphone use and inform policies aimed at protecting youth, such as delaying smartphone acquisition until age 13.

Corresponding Author: To contact the corresponding author, Ran Barzilay, MD, PhD, email ran.barzilay@pennmedicine.upenn.edu.

(doi:10.1001/jamapediatrics.2026.2118)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes

Posted June 4, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 4:15 P.M. ET, SUNDAY, JUNE 7, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the 2026 American Diabetes Association’s Scientific Sessions.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9512?guestAccessKey=0bc5930a-69a4-4659-89c3-2a73cde7550f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060726

About The Study: In participants with type 2 diabetes inadequately controlled by insulin glargine, addition of oral orforglipron significantly improved glycemic control and body weight, without increasing hypoglycemia risk, compared with placebo. Orforglipron is an oral, nonpeptide glucagon-like peptide 1 (GLP-1) receptor agonist.

Corresponding Author: To contact the corresponding author, Francesco Giorgino, MD, email francesco.giorgino@uniba.it.

(doi:10.1001/jama.2026.9512)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Insulin Costs and Use by Medicare Beneficiaries After the Inflation Reduction Act Out-of-Pocket Cap

Posted June 4, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 3:15 P.M. ET, SATURDAY, JUNE 6, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the 2026 American Diabetes Association’s Scientific Sessions.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.5975?guestAccessKey=0c80bdb6-595e-45b1-97bd-c5a714f0c368&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060626

About The Study: The Medicare $35 insulin out-of-pocket cap implemented in 2023 decreased and stabilized insulin out-of-pocket cost, increasing insulin use for people with previously high out-of-pocket cost. These findings can inform the design of policies to boost insulin access among users with high out-of-pocket cost.

Corresponding Author: To contact the corresponding author, Rebecca Myerson, PhD, email Rebecca.myerson@emory.edu.

(doi:10.1001/jama.2026.5975)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity

Posted June 4, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, SUNDAY, JUNE 7, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Diabetes Association’s Scientific Sessions.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8142?guestAccessKey=9423bd8d-ce4d-4436-a71b-b69ef4a18126&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060726

About The Study: Mazdutide, a once-weekly glucagon and glucagon-like peptide-1 (GLP-1) receptor dual agonist, provided clinically meaningful weight reduction in Chinese adults with moderate to severe obesity compared with placebo, but participants receiving the drug experienced gastrointestinal adverse reactions compared with those receiving placebo.

Corresponding Authors: To contact the corresponding authors, email Linong Ji, MD, (jiln@bjmu.edu.cn) and Lei Qian, MD, PhD, (cnradium@126.com).

(doi:10.1001/jama.2026.8142)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Defining Prenatal Care Surveillance Metrics Using Electronic Health Record Data

Posted June 3, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1295?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060526

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases

Posted June 3, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:35 A.M. ET, FRIDAY, JUNE 5, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 63rd European Renal Association Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9923?guestAccessKey=45ba1cd9-3280-445f-878c-1e1585df3fee&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060526

About The Study: In this exploratory analysis, treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist, slowed kidney function decline, reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases. These findings suggest an important role for finerenone in preserving kidney function in this population.

Corresponding Author: To contact the corresponding author, Brendon L. Neuen, MBBS, MSc, PhD, email bneuen@georgeinstitute.org.au.

(doi:10.1001/jama.2026.9923)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Enrollment Assister Perspectives of a Private Health Insurance Program for Undocumented Immigrants

Posted June 3, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1514?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060526

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

Child Welfare Involvement and Health Outcomes in Infants With Prenatal Substance Exposure

Posted June 3, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1302?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060526

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

Surgeon Perceptions of Failure to Rescue After Surgery

Posted June 3, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.17064?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060526

Patient Experiences With GLP-1 Receptor Agonists

Posted June 3, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, JUNE 5, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16951?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this qualitative study of patient experiences with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), participants described GLP-1 RA therapy functioning as a facilitator rather than a replacement for lifestyle change, emphasizing the need for behavioral interventions alongside pharmacotherapy to sustain treatment benefits. Quality of care was highly variable; thus, standardized guidelines for patient education and clinical support could improve expectation management around likely adverse effects and long-term management.

Corresponding Author: To contact the corresponding author, Isabella de Vere Hunt, MD, email Isabella.deverehunt@phc.ox.ac.uk.

(doi:10.1001/jamanetworkopen.2026.16951)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Maternal RSV Prefusion F Vaccination and Acute Respiratory Illness in Infants

Posted June 3, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, JUNE 5, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16773?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: Maternal respiratory syncytial virus prefusion F (RSVpreF) vaccination was associated with protection against RSV-associated acute respiratory illness and lower respiratory tract disease hospitalization among infants 90 days or younger. These findings provide early clinical evidence supporting the effectiveness of maternal RSVpreF vaccination in preventing RSV-associated hospitalization in infants.

Corresponding Author: To contact the corresponding author, Anne-Marie Rick, MD, MPH, PhD, email Alejandra Ruiz Leon at ruizleonap@upmc.edu.

(doi:10.1001/jamanetworkopen.2026.16596)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Treatment Delays in Early Age–Onset Colorectal Cancer

Posted June 2, 2026 by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 4, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.1335?guestAccessKey=f5cd1af9-6538-4dce-ad8c-b0d7ae27af67&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060426

About The Study: In this cross-sectional study, early age–onset colorectal cancer (EOCRC) was associated with improved overall survival compared with average age–onset colorectal cancer; however, treatment delays were independently associated with worse survival among patients with EOCRC. Language barriers could be a potentially modifiable risk factor associated with delayed treatment and may provide an opportunity to improve timely care and outcomes in EOCRC.

Corresponding Author: To contact the corresponding author, Alex C. Kim, MD, PhD, email alex.kim@utsouthwestern.edu.

(doi:10.1001/jamaoncol.2026.1335)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Online Menopause Information–Seeking Search Patterns and Commercial Content Over 2 Decades

Posted June 2, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, JUNE 4, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16596?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: From 2005 to 2025, the proportion of menopause-related searches that were related to commercial products and services increased by 15 to 20 percentage points in the United Kingdom, Australia, and the United States with no difference in the rate of increase by country. Increases appeared earlier in the U.S., with subsequent convergence across countries over time. These results suggest that individuals may be increasingly seeking nonclinical approaches to managing menopause, not only for symptom relief but also for ongoing guidance, tracking, or support outside traditional clinical encounters.

Corresponding Author: To contact the corresponding author, Francesca R. Farina, PhD, email ffarina@uchicago.edu.

(doi:10.1001/jamanetworkopen.2026.16596)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease

Posted June 2, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:45 A.M. ET, THURSDAY, JUNE 4, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the 63rd European Renal Association Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9379?guestAccessKey=2ddc7b52-ba7e-456c-b5bc-716fb792a29b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060426

About The Study: In patients with advanced chronic kidney disease at high cardiovascular risk, low-dose rivaroxaban did not reduce the risk of a composite cardiovascular outcome. Major bleeding rates were significantly higher in the low-dose rivaroxaban group compared with the placebo group.

Corresponding Author: To contact the corresponding author, Sunil V. Badve, PhD, email sbadve@georgeinstitute.org.au.

(doi:10.1001/jama.2026.9379)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes

Posted June 2, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:45 A.M. ET, THURSDAY, JUNE 4, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the 63rd European Renal Association Congress.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9639?guestAccessKey=2bc8b5d7-fdc4-4f83-9fed-00816fd204bf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060426

About The Study: Among adults in Sweden, lower measured glomerular filtration rate values were associated with higher rates of all-cause mortality, kidney failure with replacement therapy, hospitalization for heart failure, acute kidney injury, and major adverse cardiovascular events.

Corresponding Author: To contact the corresponding author, Edouard L. Fu, PhD, email e.l.fu@lumc.nl.

(doi:10.1001/jama.2026.9639)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Out-of-Pocket Costs and Health-Related Social Needs Among Households With Children

Posted June 1, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 3, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16485?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060326

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: The findings of this cohort study of U.S. households with children suggest that high out-of-pocket medical costs may make it more difficult for households to afford health-related social needs (i.e., accessing food, paying bills, and living in quality housing), potentially contributing to adverse health outcomes.

Corresponding Author: To contact the corresponding author, Michael Caniglia, PhD, MPA, email Michael.caniglia@nationwidechildrens.org.

(doi:10.1001/jamanetworkopen.2026.16485)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

What Is Ebola?

Posted June 1, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:05 A.M. ET, WEDNESDAY, JUNE 3, 2026

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10847?guestAccessKey=961ff57a-21dd-4d33-b79e-a4325795b404&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060326

About The Article: This JAMA Patient Page describes how Ebola is transmitted, how common the infection is and where outbreaks have occurred, risk factors and symptoms, and how it is diagnosed and treated.

(doi:10.1001/jama.2026.10847)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Surgeon Social Jet Lag and Patient Risk of Major Adverse Events

Posted June 1, 2026 by Jim Michalski

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, JUNE 3, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1796?guestAccessKey=258f9246-6451-41bc-ae1c-41be466cd990&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060326

About The Study: This study found that patients operated on by surgeons experiencing substantial social jet lag had a higher associated risk of major adverse events. Interventions promoting regular sleep timing and reducing circadian misalignment may improve surgeon burnout and patient safety. Social jet lag reflects the discrepancy between sleep timing on workdays and free days.

Corresponding Author: To contact the corresponding author, Léa Pascal, MPH, email lea.pascal@chu-lyon.fr.

(doi:10.1001/jamasurg.2026.1796)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Statin Use and Survival in Early Breast Cancer According to Different Intrinsic Subtypes

Posted May 29, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 2, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16375?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of patients with early breast cancer, prediagnostic statin use was not associated with higher survival; however, postdiagnostic statin use was associated with lower all-cause and breast cancer–specific mortality among patients with hormone receptor–positive intrinsic subtypes. These findings suggest that statin therapy may improve survival of patients with early hormone receptor–positive subtypes.

Corresponding Author: To contact the corresponding author, Santeri Palmi, MD, email santeri.palmi@tuni.fi.

(doi:10.1001/jamanetworkopen.2026.16375)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Residential and Transplant Center Neighborhood Segregation and Live Donor Liver Transplant

Posted May 29, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 2, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16148?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this national cohort study, living in or being wait-listed at transplant centers in high-segregation neighborhoods was associated with lower likelihood of live donor liver transplant (LDLT) access and candidates living in high-segregation neighborhoods with a larger racial and ethnic minority population compared with a larger white population had lower likelihood of LDLT. Investing in high-segregation neighborhoods to address these structural disadvantages may help improve equity in LDLT access.

Corresponding Author: To contact the corresponding author, Alexandra T. Strauss, MD, PhD, MIE, email astraus6@jhmi.edu.

(doi:10.1001/jamanetworkopen.2026.16148)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations

Posted May 29, 2026 by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 10:45 A.M. (ET), SUNDAY, MAY 31, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.2091?guestAccessKey=3856af02-1e14-467f-878f-88bfc98935a8&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053126

About The Study: In this cohort study, most participants with pathogenic variants (PVs) in breast cancer genes would not have been recommended for high-risk screening based on their clinical or clinical plus polygenic risk. PV testing therefore may identify different subsets of high-risk women than clinical risk factors and polygenic risk scores. These findings highlight the importance of population-based PV testing in risk-based screening.

Corresponding Author: To contact the corresponding author, Laura J. Esserman, MD, MBA, email laura.esserman@ucsf.edu.

(doi:10.1001/jamaoncol.2026.2091)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer

Posted May 28, 2026 by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 2:30 P.M. (ET), MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.1938?guestAccessKey=0e5d2d89-1a45-417a-9249-c906ea9ab814&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126

About The Study: In this randomized clinical trial, adding fovinaciclib to first-line aromatase inhibitor conferred significant and clinically meaningful progression-free survival benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life.

Corresponding Author: To contact the corresponding author, Binghe Xu, MD, PhD, email xubinghe@medmail.com.cn.

(doi:10.1001/jamaoncol.2026.1938)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer

Posted May 28, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 12:30 P.M. ET, MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.15509?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this randomized clinical trial of patients with advanced cancer, an app-facilitated palliative care intervention helped maintain health-related quality of life and self-efficacy and reduced acute care use compared with usual care.

Corresponding Author: To contact the corresponding author, Wing-Lok Chan, MBBS, email winglok@hku.hk.

(doi:10.1001/jamanetworkopen.2026.15509)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Conditional Medicaid Expansion and Mental Health Outcomes in Georgia

Posted May 28, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 1:15 P.M. ET, TUESDAY, JUNE 2, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13934?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this difference-in-differences analysis of national surveillance data, Georgia’s Pathways to Coverage program was associated with worsening mental health among low-income adults. These findings suggest that conditioning Medicaid eligibility on work or community engagement requirements may create additional barriers to coverage and mental health care access, with potential implications for population health and equity.

Corresponding Author: To contact the corresponding author, Sezen O. Onal, PhD, email Sezen.OzcanOnal@downstate.edu.

(doi:10.1001/jamanetworkopen.2026.13934)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer

Posted May 28, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 2:15 P.M. ET, MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8992?guestAccessKey=61a8b5d7-be3b-44df-84c7-9c1d2660be86&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126

About The Study: Adjuvant nivolumab was not associated with improved disease-free survival in patients with resected non–small cell lung cancer without sensitizing epidermal growth factor receptor and anaplastic lymphoma kinase alterations when given after planned adjuvant chemotherapy and/or radiotherapy.

Corresponding Author: To contact the corresponding author, Jamie E. Chaft, MD, email chaftj@mskcc.org.

(doi:10.1001/jama.2026.8992)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

AI Chatbot Use and Disclosure for Mental Health Among US Adolescents and Young Adults

Posted May 28, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.2015?guestAccessKey=913abc03-764d-4eed-ac18-0d1817ff8eb4&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126

About The Study: In this nationally representative survey study of U.S. adolescents and young adults, a fifth reported using AI chatbots for mental health advice. AI chatbots are already embedded in many youths’ mental health information ecosystem, underscoring the need for parents and clinicians to proactively discuss chatbot use to promote safety, appropriate expectations, and linkages to evidence-based care.

Corresponding Author: To contact the corresponding author, Ryan K. McBain, PhD, MPH, email rmcbain@rand.org.

(doi:10.1001/jamapediatrics.2026.2015)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cancer Diagnostic Delay Rates Associated With a Population-Based Screening Trial Evaluating a Cell-Free DNA Multicancer Early Detection Test

Posted May 27, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 7 P.M. ET, SATURDAY, MAY 30, 2026

Media advisory: The full study and editorials are linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6803?guestAccessKey=bbeb6f0a-1852-48bf-b718-00a96d8ad4fc&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053026

About The Study: Regional participation in a population-based multicancer early detection (MCED) screening trial was associated with a modest increase in diagnostic delay rates for patients referred for suspected head and neck, lung, and upper gastrointestinal cancers. This increase is unlikely to have materially affected interpretation of the MCED screening trial primary findings. Future trials of population-based screening interventions likely to affect demand for limited health care resources should consider monitoring for system-level spillover effects.

Corresponding Author: To contact the corresponding author, Sean Mann, MSc, email smann@rand.org.

(doi:10.1001/jama.2026.6803)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Tort Immunity and Nursing Home Staffing

Posted May 27, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 12:30 P.M. (ET), MONDAY, JUNE 1, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1534?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060126

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: In this cohort study of U.S. nursing homes, the introduction of immunity was associated with decreased overall nursing home staffing and staff per resident time. Registered nurse and licensed practical nurse to patient time was not statistically different. During the COVID-19 pandemic, many states adopted immunity from tort liability for harms to nursing home residents.

Corresponding Author: To contact the corresponding author, David S. Zingmond, MD, PhD, email dzingmond@mednet.ucla.edu.

(doi:10.1001/jamahealthforum.2026.1534)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Regulatory Definitions and Classification of Biosimilar Medications Across the 6 Regions of the World Health Organization

Posted May 27, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), SUNDAY, MAY 31, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1642?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=053126

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: This scoping review provides a detailed comparison of biosimilar regulatory guidelines across all World Health Organization regions and identified similarities and differences that may limit the transferability of data between and among countries. These barriers can potentially affect medication availability, price, access, and reimbursement of biosimilars.

Corresponding Author: To contact the corresponding author, Jonathan H. Watanabe, PharmD, MS, PhD, email Jonathan.watanabe@ucsf.edu.

(doi:10.1001/jamahealthforum.2026.1642)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Institutional Special Needs Plans and End-of-Life Outcomes for Nursing Home Residents With Dementia

Posted May 27, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), SUNDAY, MAY 31, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1649?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=053126

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: In this retrospective cohort study, Institutional Special Needs Plan (I-SNP) enrollment was associated with significantly fewer hospitalizations for nursing home residents with dementia at the end of life, with effect sizes larger for UnitedHealthcare (UHC) vs non-UHC I-SNPs. Plan maturity and volume are likely important factors impacting success.

Corresponding Author: To contact the corresponding author, Elizabeth M. White, APRN, PhD, email elizabeth_white@brown.edu.

(doi:10.1001/jamahealthforum.2026.1649)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Immigration Ban and the US Health Care Workforce

Posted May 27, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 5:15 P.M. ET, SATURDAY, MAY 30, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 AcademyHealth Annual Research Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.18999?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: The numbers of physicians and nurses immigrating from countries with complete immigration bans have significantly increased over the past decade, with these countries contributing nearly 24,000 physicians and 56,000 nurses to the entire U.S. health care workforce in 2023. Communities with physicians and nurses from banned countries were much more likely to experience ongoing health care workforce shortages. The findings of this study suggest that the recent complete immigration ban could reduce the physician and nurse workforce in the U.S. and worsen access to care across already underserved communities.

Corresponding Author: To contact the corresponding author, Hao Yu, PhD, email hao_yu@hphci.harvard.edu.

(doi:10.1001/jamanetworkopen.2026.18999)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Patient Digital Engagement With After Visit Summary in Ambulatory Care

Posted May 26, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 28, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.15020?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cross-sectional study of ambulatory visits, digital after visit summary engagement increased but remained low and was associated with a high time investment for physicians. This inefficiency in postvisit communication emphasizes the need to reconsider such communication, particularly with unmarried males, non-English-speaking populations, and publicly insured populations, and in specialty care settings.

Corresponding Author: To contact the corresponding author, Ryan Thomas Halvorson, MD, email ryan.halvorson@ucsf.edu.

(doi:10.1001/jamanetworkopen.2026.15020)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Projected US Cardiovascular Disease Burden From Heat Exposure for Future Greenhouse Gas Scenarios

Posted May 22, 2026 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 27, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2026.1240?guestAccessKey=c9c399a7-42e0-46ee-90b0-171820b0e4ed&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052726

About The Study: The findings from this study project that climate change may substantially increase heat-attributable cardiovascular disease burden across the U.S. by 2050, disproportionately affecting economically vulnerable populations and population aging amplifying this impact. The Pacific Northwest showed highest baseline burden, while Southern and Midwestern states demonstrated steepest projected increases. Heat mitigation must become central to cardiovascular prevention, with targeted interventions prioritizing vulnerable communities. The study analyzed 3,108 U.S. counties from 2010 through 2016 with projections in 2030 and 2050.

Corresponding Authors: To contact the corresponding authors, email Sanjay Rajagopalan, MD, (sanjay.rajagopalan@uhhospitals.org) and Salil V. Deo, MD, PhD, (svd14@case.edu).

(doi:10.1001/jamacardio.2026.1240)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Comparative Safety of Robotic-Assisted vs Laparoscopic Cholecystectomy in Contemporary Practice

Posted May 22, 2026 by Jim Michalski

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 27, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1585?guestAccessKey=f785a279-1bbe-445d-8456-0b2dae6e5dc0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052726

About The Study: This national analysis of Medicare beneficiaries undergoing cholecystectomy between 2020 and 2023 had 2 principal findings. First, the use of robotic-assisted cholecystectomy continued to increase substantially. Second, despite its growth, robotic-assisted cholecystectomy remained associated with higher risk-adjusted rates of bile duct injury compared with laparoscopic cholecystectomy, while differences in overall complication rates between approaches were small.

Corresponding Author: To contact the corresponding author, Cody Lendon Mullens, MD, MPH, MS, email codymu@med.umich.edu.

(doi:10.1001/jamasurg.2026.1585)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adverse Pregnancy Outcomes and Sedentary Behavior, Light-Intensity Physical Activity, and Daily Steps

Posted May 22, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 5:15 P.M. ET, WEDNESDAY, MAY 27, 2026

Media advisory: The full study is linked to this news release. This study is being presented at the 2026 American College of Sports Medicine Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6986?guestAccessKey=6bb26ffc-81d4-4ec1-91e2-bcc40b18db6b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052726

About The Study: Among pregnant individuals, sitting less with greater light-intensity movement and steps was associated with significantly lower risks of adverse pregnancy outcomes. Optimizing lighter-intensity activity patterns should be rigorously tested as a strategy to improve pregnancy health. Adverse pregnancy outcomes affect 1 in 5 pregnancies and include hypertensive disorders of pregnancy, gestational diabetes, preterm birth, and small for gestational age.

Corresponding Author: To contact the corresponding author, Bethany Barone Gibbs, PhD, email bethany.gibbs@hsc.wvu.edu.

(doi:10.1001/jama.2026.6986)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Hearing Aids for Adults With Mild to Moderate Hearing Loss

Posted May 22, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 27, 2026

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4740?guestAccessKey=8330ca95-94c4-4ffa-8748-5114a9e95771&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052726

About The Article: This article discusses hearing aids for adults with mild to moderate hearing loss, including hearing aid function and limitations and prescription vs over-the-counter hearing aid devices.

Corresponding Author: To contact the corresponding author, Karina De Sousa, PhD, email karina.swanepoel@up.ac.za.

(doi:10.1001/jama.2026.4740)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prevalence of Diagnosed Type 2 Diabetes Among US Children and Adolescents

Posted May 21, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 26, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1539?guestAccessKey=6e5936ab-e69b-4936-a18a-ec8ddcb82dca&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052626

About The Study: This nationally representative study estimating type 2 diabetes (T2D) prevalence among U.S. children and adolescents found that the prevalence among those ages 10 to 17 was nearly 4-fold higher than a 2017 estimate among those ages 10 to 19. The substantial increase in prevalence is alarming given T2D’s lifetime risk of debilitating complications and premature deaths.

Corresponding Authors: To contact the corresponding authors, email Wei Bao, MD, PhD, (wbao@ustc.edu.cn) and Guifeng Xu, MD, PhD, (xguifeng365@ustc.edu.cn).

(doi:10.1001/jamapediatrics.2026.1539)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Plasma eMTBR-tau243 and %p-tau217 for Biological Staging of Alzheimer Disease

Posted May 21, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 26, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1405?guestAccessKey=7a4721e2-ae1b-41fb-b272-4ae1ffbdb228&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052626

About The Study: A plasma-based staging model using eMTBR-tau243 and %p-tau217 demonstrated strong concordance with positron emission tomography-based staging and clinical severity of Alzheimer disease. Plasma-based staging may provide a scalable, minimally invasive approach to biological stratification of Alzheimer disease, with potential value for treatment selection and clinical trial enrichment.

Corresponding Authors: To contact the corresponding authors, email Gemma Salvado, PhD (gemma.salvado@med.lu.se) and Oskar Hansson, MD, PhD (oskar.hansson@med.lu.se).

(doi:10.1001/jamaneurol.2026.1405)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Efficacy and Safety of Ecopipam for Tourette Syndrome

Posted May 21, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 26, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1431?guestAccessKey=c85179fe-77e7-42fe-943f-751d1bee8c12&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052626

About The Study: Among patients with Tourette syndrome, ecopipam, a selective dopamine D1 receptor antagonist, maintained tic suppression and was well tolerated for up to 24 weeks, without clinically significant metabolic or movement disorder adverse effects.

Corresponding Author: To contact the corresponding author, Donald L. Gilbert, MD, MS, email donald.gilbert@cchmc.org.

(doi:10.1001/jamaneurol.2026.1431)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Medication and Acute Care Use in Young Adults With Opioid Use Subject to Medicaid Prescription Caps

Posted May 20, 2026 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, MAY 22, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2026.1187?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052226

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: In this cohort study, Medicaid prescription caps were associated with lower overall use of prescription medications and greater frequency of acute care use among young adults with opioid use disorder.

Corresponding Author: To contact the corresponding author, Christopher M. Santostefano, MPH, RN, email christopher_santostefano@brown.edu.

(doi:10.1001/jamahealthforum.2026.1187)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Antenatal Opioid Exposure and Cerebral Cortical Maturation in Newborns

Posted May 20, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 22, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.14115?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This large, multisite cohort study found that antenatal opioid exposure was associated with impaired cerebral cortical folding in newborns. The extent of cerebral cortical impairment differed based on the opioid type and presence of polysubstance exposure. Continued longitudinal neuroimaging and neurodevelopmental assessments are currently underway to examine the trajectory of brain development and clinical significance of these early cortical changes, potentially informing early interventions to support neurodevelopment in this vulnerable population.

Corresponding Author: To contact the corresponding author, Catherine Limperopoulos, PhD, email climpero@childrensnational.org.

(doi:10.1001/jamanetworkopen.2026.14115)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous

Posted May 19, 2026 by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, MAY 21, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.1391?guestAccessKey=45a915d2-c5ef-4404-8605-38cd6741508b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052126

About The Study: In this study, dropping the cancer label from grade group (GG)1 prostate disease and redefining GG1 prostate disease as a precancerous lesion led to a net reduction in estimated prostate cancer deaths. Proponents for retaining the cancer label for GG1 prostate disease should argue relabeling would have close to zero effects on screening rates or that other harms outweigh the benefits of reduced prostate cancer mortality.

Corresponding Author: To contact the corresponding author, Andrew J. Vickers, PhD, email vickersa@mskcc.org.

(doi:10.1001/jamaoncol.2026.1391)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Heart Failure Trajectories After Guideline-Directed Medical Therapy

Posted May 19, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 21, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13955?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052126

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: The findings of this cohort study underscore a gap between evidence and practice. Two-thirds of patients with newly identified heart failure with reduced ejection fraction did not undergo left ventricular ejection fraction reassessment, limiting opportunities to confirm persistence, evaluate reverse remodeling, and identify candidates for treatment. Receipt of guideline-directed medical therapy was modest across groups, even among patients with persistent heart failure with reduced ejection fraction, who derive the greatest benefit.

Corresponding Author: To contact the corresponding author, Brianna M. Goodwin Cartwright, MS, email briannac@truveta.com.

(doi:10.1001/jamanetworkopen.2026.13955)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Hospital and Emergency Department Pediatric Capability, Patient Characteristics, and Radiology Imaging for Children

Posted May 18, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 20, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13689?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of pediatric emergency department visits, increased pediatric capability was not associated with differences in the patterns of imaging utilization by insurance status or race and ethnicity. Additional efforts are needed to ensure that pediatric capability improves quality and equity of care.

Corresponding Author: To contact the corresponding author, Margaret E. Samuels-Kalow, MD, MPhil, MSHP, email msamuels-kalow@mgb.org.

(doi:10.1001/jamanetworkopen.2026.13689)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Nationwide Implementation of Multimodal Prehabilitation and Complications After Colorectal Cancer Surgery

Posted May 18, 2026 by Jim Michalski

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 20, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1519?guestAccessKey=f2ae35ad-6bec-4abd-aaf8-5e097a8c9f26&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026

About The Study: The results of this cohort study show that implementation of a uniform multimodal prehabilitation program for unselected patients undergoing colorectal cancer surgery was associated with reduced complication rates and length of hospital stay across all age and American Society of Anesthesiologists score subgroups.

Corresponding Author: To contact the corresponding author, Gerrit D. Slooter, MD, PhD, email g.slooter@mmc.nl.

(doi:10.1001/jamasurg.2026.1519)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Interleukin 6 as a Treatment Target for Depression

Posted May 18, 2026 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 20, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1053?guestAccessKey=b62cde62-853f-4f80-a300-55745bef474a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026

About The Study: This proof-of-concept randomized clinical trial provides insights into the therapeutic potential of interleukin 6 (IL-6) or IL-6 receptor inhibition for depression and highlights suitable patient selection methods. Interleukin 6, a keystone inflammatory cytokine, is a credible mechanistic candidate for causing depression.

Corresponding Authors: To contact the corresponding authors, email Éimear M. Foley, PhD (eimear.foley@bristol.ac.uk) and Golam M. Khandaker, PhD, (golam.khandaker@bristol.ac.uk).

(10.1001/jamapsychiatry.2026.1053)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Weight Loss in Older Patients With Persistent Atrial Fibrillation

Posted May 15, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 20, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.5787?guestAccessKey=1d43f9b4-9d6e-4cf8-ac42-715b31607042&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052026

About The Study: In older patients with overweight and persistent atrial fibrillation, a low-calorie diet and behavioral support program was associated with significant weight loss at 8 months with no safety concerns but did not affect atrial fibrillation symptoms, atrial fibrillation burden, cardiac remodeling, or the need for further rhythm control interventions.

Corresponding Author: To contact the corresponding author, Rohan Wijesurendra, MB, BChir, DPhil, email rohan.wijesurendra@ndph.ox.ac.uk.

(doi:10.1001/jama.2026.5787)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Cognitive Trajectories and Subsequent Accelerometer-Measured Movement Behavior in Older Adults

Posted May 15, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 19, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13399?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051926

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of older adults, participants with less favorable long-term memory trajectories were subsequently less active and more sedentary, suggesting that later-life activity patterns may partly reflect cognitive change.

Corresponding Author: To contact the corresponding author, Mikaela Bloomberg, PhD, email mikaela.bloomberg.19@ucl.ac.uk.

(doi:10.1001/jamanetworkopen.2026.13399)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Life Expectancy in Chronic Obstructive Pulmonary Disease

Posted May 14, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 9:25 A.M. (ET), SUNDAY, MAY 17, 2026

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Thoracic Society 2026 International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.0207?guestAccessKey=f41c3b9b-5b77-429e-aeec-bf69a05ba129&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051726

About The Study: In this cohort study, chronic obstructive pulmonary disease (COPD) was associated with lower life expectancy, including in adults who never smoked.

Corresponding Authors: To contact the corresponding authors, email Surya P. Bhatt, MD, MSPH, (sbhatt@uabmc.edu) and Elizabeth C. Oelsner, MD, DrPH, (eco7@cumc.columbia.edu).

(doi:10.1001/jamainternmed.2026.0207)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Smartphone Use on School Nights in the Adolescent Brain Cognitive Development Study

Posted May 14, 2026 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1707?guestAccessKey=4122c6c3-eca9-4ba4-a326-9a16d86a8a92&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

Studies Being Presented at the American Thoracic Society 2026 International Conference

Posted May 14, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 2:15 P.M. ET, MONDAY, MAY 18, 2026

Media advisory: The full studies and editorial are linked to this news release. These studies are being presented at the American Thoracic Society 2026 International Conference.

Remote Multicomponent Rehabilitation in Intensive Care Unit Survivors

A 6-week, multicomponent, rehabilitation program did not improve health-related quality of life at 8 weeks after discharge in ICU survivors who required mechanical ventilation.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7401?guestAccessKey=d5b00e3e-6546-422b-b170-7f9751a5f648&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

# # #

4% Tetrasodium EDTA to Prevent Central Venous Access Device–Associated Complications

In an adult critical care setting, use of 4% tetrasodium EDTA (a potent anticoagulant, antimicrobial, and antibiofilm agent) as a locking fluid reduced a composite outcome of central venous access device complications compared with control.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6025?guestAccessKey=8779014b-32fb-425b-bb86-4d10751eb4ba&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Studies Being Presented at the American Thoracic Society 2026 International Conference

Posted May 14, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:15 A.M. ET, MONDAY, MAY 18, 2026

Media advisory: The full studies are linked to this news release. These studies are being presented at the American Thoracic Society 2026 International Conference.

Biomarker-Based Eligibility for Lung Cancer Screening

Compared with questionnaire-based approaches, the protein-based INTEGRAL-Risk model improved short-term prediction of lung cancer in people with a smoking history. This model has potential to improve selection of high-risk individuals who are most likely to benefit from lung cancer screening.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8044?guestAccessKey=0eae2f18-12f7-4159-8985-b66ab1adad7a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

# # #

Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy

Transbronchial lung biopsy performed with a 1.1-mm cryoprobe had a significantly higher diagnostic yield compared with 2.0-mm forceps in a group of patients with lung nodules or masses, lung transplant, and diffuse parenchymal lung disease.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7908?guestAccessKey=98bf13bc-cae8-472b-8028-0d59c8856bcf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Disparities in Inhaler Utilization Among US Adults With Asthma

Posted May 14, 2026 by Jim Michalski

This study is being published to coincide with the American Thoracic Society 2026 International Conference

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.7613?guestAccessKey=2e69ddd0-1169-4e3a-a4c1-87ea3a04cb1e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

An AI–Enabled Cardiopulmonary Resuscitation Instructor

Posted May 14, 2026 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 18, 2026

Media advisory: The full study and editor’s note are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.1552?guestAccessKey=bb1c143e-d5c9-4ec1-b89f-3dc073892f2b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

About The Study: The findings of this study suggest that AI-enabled cardiopulmonary resuscitation (CPR) instruction shows promise for supporting bystanders. Further validation in diverse, general population settings is warranted to define the role of AI-based CPR instruction as a scalable public health intervention for out-of-hospital cardiac arrests.

Corresponding Author: To contact the corresponding author, John W. Ayers, PhD, MA, email ayers.john.w@gmail.com.

(doi:10.1001/jamainternmed.2026.1552)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Amateur Soccer Heading and Acute Elevations in Blood-Based p-Tau217 and S100B

Posted May 14, 2026 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 18, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.1224?guestAccessKey=b9a4865f-e420-4d12-adfc-22347d416678&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

About The Study: The findings of this case-control study show that soccer heading was associated with acute increases in blood biomarkers of neural damage, including dose-response relationships. These findings suggest that amateur-level heading may acutely affect neural integrity.

Corresponding Author: To contact the corresponding author, Marsh Konigs, PhD, email m.konigs@amsterdamumc.nl.

(doi:10.1001/jamaneurol.2026.1224)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Dual Immunization Against RSV With RSVpreF and Nirsevimab

Posted May 14, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 18, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1346?guestAccessKey=e2814820-b22a-4ec5-9158-da67534c2541&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

About The Study: This cohort study describes respiratory syncytial virus (RSV)-associated lower respiratory tract infection hospitalizations among infants in France who received both maternal RSVpreF vaccination and nirsevimab during the 2024-2025 RSV season.

Corresponding Author: To contact the corresponding author, Ludovic Tréluyer, MD, PhD, email ludovic.treluyer@ansm.sante.fr.

(doi:10.1001/jamapediatrics.2026.1346)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

High-Dose Vitamin D3 Supplementation During Pregnancy and Test-Based Cognitive Performance at Age 10

Posted May 14, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 18, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.11464?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This post hoc analysis of a randomized clinical trial suggests that high-dose vitamin D3 supplementation in pregnancy is positively associated with visual memory, verbal memory, and flexibility or set shift among offspring measured at age 10 years. These findings strengthen evidence on the association of prenatal vitamin D exposure with childhood cognition.

Corresponding Author: To contact the corresponding author, Bo Chawes, MD, PhD, DMSc, email chawes@copsac.com.

(doi:10.1001/jamanetworkopen.2026.11464)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression

Posted May 13, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12589?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this randomized clinical trial of major depressive disorder, a single dose of psilocybin was associated with rapid antidepressant effects, observed by day 2 and persisting for more than 3 months on secondary outcomes; psilocybin was generally well tolerated, but some individuals required additional support after dosing due to anxiety. These results suggest that psilocybin may provide a rapid and relatively long-lasting antidepressant effect on major depressive disorder, warranting further investigation into repeated dosing or adjunctive treatment strategies.

Corresponding Author: To contact the corresponding author, Hampus Yngwe, MD, MSc, email hampus.yngwe@ki.se.

(doi:10.1001/jamanetworkopen.2026.12589)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Armed Conflict and Penetrating Traumatic Brain Injury in Children in the Gaza Strip

Posted May 13, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.13094?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This study assessed functional outcomes at hospital discharge among children and adolescents who sustained penetrating traumatic brain injury (TBI) during armed conflict in the Gaza Strip and found there was substantial morbidity and mortality. Penetrating TBI, characterized by a breach of the dura mater caused by a projectile or fragment, represents one of the most fatal war-related injuries. Survivors frequently endure neurological impairments alongside long-term psychosocial challenges.

Corresponding Author: To contact the corresponding author, Mohammed Asfa, MD, email asfa1991@gmail.com.

(doi:10.1001/jamanetworkopen.2026.13094)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Management of Spontaneous Abortion Among Commercially Insured Individuals in the United States After Dobbs v Jackson

Posted May 13, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 18, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6344?guestAccessKey=59038f2d-d29e-4c32-90dc-1e5e96cf6cc0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051826

About The Study: State-level abortion bans were associated with a shift in spontaneous abortion management away from medication and toward expectant approaches, with persistent reliance on suboptimal misoprostol-only regimens in ban states, suggesting a decrease in management options for individuals with spontaneous abortion in ban states.

Corresponding Author: To contact the corresponding author, Maria I. Rodriguez, MD, MPH, email rodrigma@ohsu.edu.

(doi:10.1001/jama.2026.6344)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Recent COVID-19 Vaccination and Risk of SARS-CoV-2 Transmission

Posted May 13, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 15, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12609?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051526

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study, recent COVID-19 vaccination was associated with a reduced risk of SARS-CoV-2 transmission. These findings suggest that COVID-19 vaccination may have an indirect benefit of decreasing transmission and thus reducing overall exposure to SARS-CoV-2.

Corresponding Author: To contact the corresponding author, Sarah E. Smith-Jeffcoat, MPH, email uyi7@cdc.gov.

(doi:10.1001/jamanetworkopen.2026.12609)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Adverse Pregnancy Outcomes and Cardiovascular Health Among Offspring in Early Adulthood

Posted May 12, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 14, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.6783?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this longitudinal cohort study of mother-child dyads enrolled at the child’s birth, exposure to adverse pregnancy outcomes during gestation, particularly hypertensive disorders of pregnancy, was associated with suboptimal cardiovascular health and arterial injury among offspring in early adulthood. The findings suggest optimizing pregnancy health may support offspring cardiovascular health into early adulthood.

Corresponding Author: To contact the corresponding author, Nilay S. Shah, MD, MPH, email nilay.shah@northwestern.edu.

(doi:10.1001/jamanetworkopen.2026.6783)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias

Posted May 12, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 14, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12601?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051426

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this case-control study, exposures to ambient particulate matter with a diameter less than 2.5 μm or nitrogen dioxide were each associated with increased risks of dementia with Lewy bodies and Parkinson disease–related dementia, with a greater magnitude of association for risk of dementia with Lewy bodies. These findings warrant concern about the impact of air pollution on brain health.

Corresponding Author: To contact the corresponding author, Dimitry S. Davydow, MD, MPH, email ddavydow@ufl.edu.

(doi:10.1001/jamanetworkopen.2026.12601)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Trends in Metabolic Bariatric Surgery Utilization in the Era of GLP-1s, 2022-2024

Posted May 11, 2026 by Jim Michalski

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 13, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2026.1343?guestAccessKey=bf60d8c4-391f-4322-bfd4-8bc3a52a068a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051326

About The Study: This study found a profound decrease in the utilization of metabolic bariatric surgery, with a 34.1% decrease from 2022 to 2024, while glucagon-like peptide-1 receptor agonist (GLP-1) use increased by 140.4% over the same period. Given the year-on year declines in metabolic bariatric surgery utilization, these trends may continue given the persistent and growing prescribing of GLP-1s.

Corresponding Author: To contact the corresponding author, Robert J. Calzaretta Jr, MIDS, email robert.calzaretta@analysisgroup.com.

(doi:10.1001/jamasurg.2026.1343)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Pragmatic Parental Support to Mitigate Burnout Among Pregnant and Postpartum Trainees

Posted May 11, 2026 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 13, 2026

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.5663?guestAccessKey=cc52f287-8aca-4724-81c0-dbf5048e1a4d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051326

About The Study: Occupational burnout threatens care quality, workforce retention, and physician health. In this study, a parental support package significantly mitigated postpartum burnout among childbearing physicians in training.

Corresponding Author: To contact the corresponding author, Erika L. Rangel, MD, MS, email erangel@mgh.harvard.edu.

(doi:10.1001/jama.2026.5663)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Firearm Storage in Households With Children

Posted May 8, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 12, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12191?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this survey study of adult firearm owners who lived in households with children younger than 18 years, more than 1 in 5 reported that at least 1 firearm in their household was both loaded and unlocked, a practice more common when all children in the household were teenagers. More effective approaches to motivating parents to make their firearms inaccessible to both their teenagers and their younger children are needed.

Corresponding Author: To contact the corresponding author, Matthew Miller, MD, MPH, ScD, email ma.miller@northeastern.edu.

(doi:10.1001/jamanetworkopen.2026.12191)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Stage IV Breast Cancer Incidence and Survival, 2010-2021

Posted May 8, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 12, 2026

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.12042?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of individuals with stage IV breast cancer, incidence increased significantly overall, across ages, and for both sexes from 2010 through 2021. The percentage of individuals with stage IV vs stages I to III diagnoses also increased. Although overall survival improved, research is warranted to determine factors contributing to increased incidence, including potential changes in natural history of breast cancer, disease screening, and incidence and mortality of other conditions.

Corresponding Author: To contact the corresponding author, Jose P. Leone, MD, email josep_leone@dfci.harvard.edu.

(doi:10.1001/jamanetworkopen.2026.12042)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Ivermectin-Benzimidazole Prescribing Following Celebrity Endorsement

Posted May 8, 2026 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 12, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.16780?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051226

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: Ivermectin-benzimidazole prescribing rose rapidly following celebrity endorsement in January 2025, with disproportionate increases among male patients, white patients, residents of the U.S. South, and individuals with cancer. The elevated prescribing observed among patients with cancer is particularly concerning; individuals facing life-threatening illness may delay or forgo conventional treatments in favor of unproven therapies, potentially allowing their disease to progress.

Corresponding Author: To contact the corresponding author, Michelle S. Rockwell, PhD, email msrock@vt.edu.

(doi:10.1001/jamanetworkopen.2026.16780)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

State-Level Differences in HPV Vaccine Uptake Among 13- to 17-Year-Old Adolescents

Posted May 7, 2026 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 11, 2026

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.1338?guestAccessKey=27364266-7508-4b0d-974b-c5adf2563386&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051126

About The Study: This cross-sectional study demonstrates substantial state-level variation in human papillomavirus (HPV) vaccine uptake among U.S. adolescents, even after adjustment for key sociodemographic factors. Several Northeastern states, including Massachusetts, Rhode Island, and New Hampshire, exhibited significantly higher odds of HPV vaccination compared with the reference state, Alabama, whereas multiple Southern states, particularly Mississippi, Georgia, Oklahoma, Kentucky, and West Virginia had significantly lower odds of uptake.

Corresponding Author: To contact the corresponding author, Chinenye Lynette Ejezie, PhD, MPH, email cejezie@towson.edu.

(doi:10.1001/jamapediatrics.2026.1338)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.